Free Trial
NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Price, News & Analysis

Revolution Medicines logo
$46.48 -0.10 (-0.21%)
As of 11:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Revolution Medicines Stock (NASDAQ:RVMD)

Advanced

Key Stats

Today's Range
$46.25
$47.02
50-Day Range
$34.70
$46.71
52-Week Range
$29.17
$62.40
Volume
103,966 shs
Average Volume
1.91 million shs
Market Capitalization
$8.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.64
Consensus Rating
Moderate Buy

Company Overview

Revolution Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

RVMD MarketRank™: 

Revolution Medicines scored higher than 86% of companies evaluated by MarketBeat, and ranked 142nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Revolution Medicines has a consensus price target of $74.64, representing about 60.6% upside from its current price of $46.48.

  • Amount of Analyst Coverage

    Revolution Medicines has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Revolution Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Revolution Medicines are expected to decrease in the coming year, from ($3.49) to ($3.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revolution Medicines is -10.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revolution Medicines is -10.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Revolution Medicines has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Revolution Medicines' valuation and earnings.
  • Percentage of Shares Shorted

    9.66% of the outstanding shares of Revolution Medicines have been sold short.
  • Short Interest Ratio / Days to Cover

    Revolution Medicines has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in Revolution Medicines has recently increased by 9.20%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Revolution Medicines does not currently pay a dividend.

  • Dividend Growth

    Revolution Medicines does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.66% of the outstanding shares of Revolution Medicines have been sold short.
  • Short Interest Ratio / Days to Cover

    Revolution Medicines has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in Revolution Medicines has recently increased by 9.20%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Revolution Medicines has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Revolution Medicines this week, compared to 8 articles on an average week.
  • Search Interest

    15 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,242,708.00 in company stock.

  • Percentage Held by Insiders

    Only 8.20% of the stock of Revolution Medicines is held by insiders.

  • Percentage Held by Institutions

    94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Revolution Medicines' insider trading history.
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RVMD Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
See More Headlines

RVMD Stock Analysis - Frequently Asked Questions

Revolution Medicines' stock was trading at $43.74 at the start of the year. Since then, RVMD shares have increased by 6.3% and is now trading at $46.4840.

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Wednesday, August, 6th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.37. Revolution Medicines's revenue for the quarter was up .0% compared to the same quarter last year.
Read the conference call transcript
.

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Revolution Medicines' top institutional shareholders include Praxis Investment Management Inc. and GAMMA Investing LLC. Insiders that own company stock include Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Lin Wei, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber.
View institutional ownership trends
.

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/06/2025
Today
10/06/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVMD
CIK
1628171
Fax
N/A
Employees
250
Year Founded
2014

Price Target and Rating

High Price Target
$99.00
Low Price Target
$64.00
Potential Upside/Downside
+60.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$600.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.78%
Return on Assets
-35.63%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
11.79
Quick Ratio
11.79

Sales & Book Value

Annual Sales
$11.58 million
Price / Sales
751.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.47 per share
Price / Book
3.46

Miscellaneous

Outstanding Shares
186,930,000
Free Float
171,604,000
Market Cap
$8.71 billion
Optionable
Optionable
Beta
1.27

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:RVMD) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners